- Home
- KIND vs TBPH Comparison
KIND vs TBPH Comparison
Compare KIND & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIND
- TBPH
- Stock Information
- Founded
- KIND 2011
- TBPH 2013
- Country
- KIND United States
- TBPH United States
- Employees
- KIND N/A
- TBPH N/A
- Industry
- KIND Computer Software: Programming Data Processing
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- KIND Technology
- TBPH Health Care
- Exchange
- KIND Nasdaq
- TBPH Nasdaq
- Market Cap
- KIND 608.3M
- TBPH 536.5M
- IPO Year
- KIND N/A
- TBPH N/A
- Fundamental
- Price
- KIND $1.62
- TBPH $11.15
- Analyst Decision
- KIND Buy
- TBPH Strong Buy
- Analyst Count
- KIND 4
- TBPH 5
- Target Price
- KIND $2.56
- TBPH $16.60
- AVG Volume (30 Days)
- KIND 2.1M
- TBPH 245.1K
- Earning Date
- KIND 08-06-2025
- TBPH 08-04-2025
- Dividend Yield
- KIND N/A
- TBPH N/A
- EPS Growth
- KIND N/A
- TBPH N/A
- EPS
- KIND N/A
- TBPH N/A
- Revenue
- KIND $248,306,000.00
- TBPH $65,266,000.00
- Revenue This Year
- KIND $1.77
- TBPH $43.18
- Revenue Next Year
- KIND $10.72
- TBPH N/A
- P/E Ratio
- KIND N/A
- TBPH N/A
- Revenue Growth
- KIND 12.01
- TBPH 6.11
- 52 Week Low
- KIND $1.32
- TBPH $7.44
- 52 Week High
- KIND $3.00
- TBPH $11.82
- Technical
- Relative Strength Index (RSI)
- KIND 55.06
- TBPH 62.38
- Support Level
- KIND $1.55
- TBPH $10.87
- Resistance Level
- KIND $1.66
- TBPH $11.44
- Average True Range (ATR)
- KIND 0.07
- TBPH 0.29
- MACD
- KIND 0.00
- TBPH -0.00
- Stochastic Oscillator
- KIND 68.75
- TBPH 71.92
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services. It offers a comprehensive suite of advertising solutions designed to deliver exceptional value for businesses of all size.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).